[Antiestrogen therapy of patients with uterine cancer].
It has been widely accepted that the estrogen is one of the contributing factors to the development of endometrial cancer of the uterus. The objective responsiveness of recurrent endometrial cancer to medroxyprogesterone acetate (MPA) has been substantiated. Many researchers have examined whether the anti-estrogenic agents could be the choice of treatment of endometrial cancer including tamoxifen (TAM), aromatase inhibitors, danazol and luteinizing releasing hormone (LHRH)-agonist as an adjunctive endocrine therapy. In this review, we discussed the pharmacological and clinical aspects of these new agents.
Sugimura
M
M
Department of Obstetrics and Gynecology, Hamamatsu Medical Center.
Terao
T
T
D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004965:Estrogen Antagonists; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D003613:Danazol